Podcasts about eligible

Ep. 170 features John Wright from StatsDrone, a business intelligence platform helping affiliates eliminate revenue leak and unlock more value from their data. John shares how the company is centralizing fragmented affiliate stats, building tools for operators, and uncovering hidden opportunities in iGaming's affiliate ecosystem.   Hear them discuss: The origin story from professional gambler to affiliate tech founder How revenue leak inspired the earliest version of StatsDrone Why “business intelligence” became the heart of their value proposition Who uses the platform today—from SEO affiliates to large networks How StatsDrone is building a global map of affiliate sites and links The surprising ROI hiding in broken tracking and closed casino Why affiliate CRM remains an underdeveloped opportunity How operators and affiliate managers are starting to use their insights What it's like navigating investor interest and potential exit offers His two-year vision to unlock billions in affiliate-side revenue optimization   Applications now open for SBC Summit First Pitch competition returning to Lisbon this September 16-18. Eligible startups can submit their applications until July 25 for a shot at over $100,000 worth of prizes.    Catch the video version of this episode here.   Learn more

(00:00) The guys talk about their plans to stay out of the brutal heat today, the debate between pool and beach, and much more. (16:06) The guys give an update with Andrew Callahan regarding the Patriots rookies and their progress heading into camp this summer. (31:00) The guys give their thoughts on new former Bruins that are now able to be inducted into the hall of fame, including Zdeno Chara, Tuukka Rask, and more. CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

TBD

CTL Script/ Top Stories of June 13th Publish Date: June 13th   Pre-Roll: From the Ingles Studio Welcome to the Award-Winning Cherokee Tribune Ledger Podcast  Today is Friday, June 13th and Happy Birthday to Tim Allen I’m Peyton Spurlock and here are the stories Cherokee is talking about, presented by Times Journal Cherokee County Students Win Gold in Summer Special Olympics GDOT Wants Your Input on Towne Lake Parkway and I-575 Bomb Babes Opens at The Outlet Shoppes in Woodstock Plus, Leah McGrath from Ingles Markets on sodas We’ll have all this and more coming up on the Cherokee Tribune-Ledger Podcast, and if you’re looking for Community news, we encourage you to listen and subscribe!  Commercial: MILL ON ETOWAH REV GENERIC_FINAL STORY 1: Cherokee County Students Win Gold in Summer Special Olympics Cherokee County School District students excelled at the 2025 State Summer Special Olympics, earning gold in various events at Emory University. The Cherokee County Special Olympics soccer team won gold, while individual students claimed top honors in cheer, flag football, soccer, swimming, and track. Notable achievements include standout performances in swimming by Otto Arreaza and Daniel Cannon, and track victories by Imani Cherry and Lorelei Lyu. The Olympians will be honored at an upcoming school board meeting alongside Adapted PE teacher and Special Olympics coordinator Ben Farist. STORY 2: GDOT Wants Your Input on Towne Lake Parkway and I-575 The Georgia Department of Transportation (GDOT) and the Federal Highway Administration are seeking public input on proposed improvements to the I-575 and Towne Lake Parkway interchange in Cherokee County. Public comments can be submitted online through July 7 via GDOT’s project website. The $12.9 million project, funded by federal and local contributions, aims to enhance traffic flow with added turn lanes, wider shoulders, and intersection upgrades. Improvements include extended turn lanes on Towne Lake Parkway and I-575 ramps, as well as additional lanes and turn options at the Woodstock Parkway intersection. Public input is encouraged to shape the project. STORY 3: Bomb Babes Opens at The Outlet Shoppes in Woodstock Bomb Babes, a gourmet cake bomb bakery founded by Kathryn Cruz, celebrated the opening of its first storefront in Woodstock on June 10. Previously operating from her home kitchen and pop-up events, Cruz launched the brick-and-mortar location at The Outlet Shoppes of Atlanta on May 23. Known for oversized cake truffles, Bomb Babes evolved from a hot chocolate bomb business. Cruz, recently named one of Cherokee County’s Top 10 in 10 Young Professionals, credits local support and entrepreneurial programs for her success. With plans to franchise next year, Cruz aims to make Bomb Babes a household name like Crumbl Cookies. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info.    Break: STORY 4: Cherokee Sheriff’s Foundation Announces Scholarship Recipients The Cherokee Sheriff’s Foundation has announced its 2025 college scholarship recipients, awarding $1,000 scholarships to 10 students. These scholarships honor the children of Cherokee Sheriff’s Office and Marshals Office employees for their academic excellence and community service. This year’s recipients are Anabelle Jordan, Anakate Cox, Autumn Herrin, Avery Shaw, Issac Martin, Jaden Bedoya, Katelynn Carter, Shaun Pinyan, Sophie Baker, and Thomas Pinyan III. For more information or to support the foundation, visit their website. STORY 5: How to Vote Absentee in Cherokee’s Aug. 26 Elections Applications for absentee ballots are now open for Cherokee County’s Aug. 26 special elections, which will fill the Georgia Senate District 21 and Cherokee County Board of Commissioners District 1 seats. Eligible voters can apply online, by mail, fax, email, or in person, with the deadline to apply set for Aug. 15. Absentee ballots will be mailed out 22-29 days before the election. Completed ballots can be submitted via mail, in person, or at designated dropbox locations during early voting hours. For details, visit the Cherokee County Elections website. Commercial: And now here is Leah McGrath from Ingles Markets on sodas We’ll have closing comments after this.   COMMERCIAL: Ingles Markets 10   SIGN OFF –   Thanks again for hanging out with us on today’s Cherokee Tribune Ledger Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.tribuneledgernews.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com Etowah Mill #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Jennie Garth and Jana Kramer are playing matchmaker! These two sit down with former "Bachelorette" winner JP Rosenbaum to hear how he and his ex-wife are co-parenting, how hard dating is in Miami, and what he's looking for in his chapter 2! Plus, JP gives the details women want to know - he's giving you the truth about what women should have (and should avoid) on their dating profiles! Email us at: IDOPOD@iheartradio.com or call us at 844-4-I Do Pod (844-443-6763)Follow I Do, Part 2 on Instagram and TikTokSee omnystudio.com/listener for privacy information.

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

The Second Chance Amendment Act of 2022, as enacted in March 2025, amends D.C.'s outdated record-sealing laws to align them with contemporary record relief laws in other states. Succinctly stated, the Act provides a comprehensive framework for expunging and sealing certain records. In doing so, it can help remove the stigma of past convictions and make it easier for eligible individuals to get a job, rent an apartment, or secure a loan—all while still ensuring public safety. Because navigating the Act's eligibility requirements can be tricky, joining us to explain it all are D.C. Justice Lab's founder and Executive Director, Patrice Sulton; and Policy Counsel, Nye Winslow, with host Robin Earnest from the Steering Committee of the DC Bar's Criminal Law and Individual Rights Steering Committee.Robin M. Earnest serves on the Steering Committee for the DC Bar's Criminal Law and Individual Rights Community and received the Bar's 2024 Lawyer of the Year Award for her Community service. Robin is also a member of the D.C. Court of Appeals Committee on Admissions; and she teaches a course on Litigation With the Federal Government as a Professional Lecturer at GW Law School. Robin founded The Earnest Law Firm and is a CJA Panel attorney with the U.S. Courts of Appeals for the Fourth and D.C. Circuits, as well as the D.C. Court of Appeals.Patrice A. Sulton is the founder and executive director for DC Justice Lab–a team of law and policy experts researching, organizing, and advocating for large-scale changes to the District's criminal legal system. She teaches Adjudicatory Criminal Procedure and Trial Advocacy as a Professional Lecturer at GW Law School and was awarded the Distinguished Adjunct Teaching Award in 2021. She also serves on the Board of Directors for the Network of Victim Recovery of DC. Most recently, Patrice served on DC's Criminal Code Reform Commission; the Police Reform Commission; and its Jails and Justice Task Force.Nye Winslow is the Policy Counsel with the DC Justice Lab where he shapes policy campaigns and offers legal expertise on policy issues. Prior to joining DC Justice Lab Nye worked as a Legal Consultant at the NAACP's Office of the General Counsel and focused on claims of racial discrimination in voting rights, policing, redistricting, and child welfare.

Luke and Paul Calvisi discuss if Devin Booker has more leverage than any other player in the NBA and talk to Arizona Cardinals wide receiver Zay Jones.

See omnystudio.com/listener for privacy information.

Dive into the latest college football news with Joe DeLeone and Blake Ruffino! In this episode: Texas A&M 2025 Preview: Can Mike Elko and QB Marcel Reed lead the Aggies back to dominance? Big 12 vs SEC Drama: Brett Yormark responds to Greg Sankey in the growing Playoff expansion battle. Mike Leach Hall of Fame Watch: A legendary coach becomes eligible—should he be a lock?

From the scarcity of eligible men to the rise of sober dating, J&J explore in this Friday Feels ep how gender dynamics and societal shifts are reshaping the current dating landscape! The hosts unpack why ambitious women feel like they're settling and why men seem overwhelmed by options. Listener emails spark juicy debates, like whether it's a red flag to bring your own Crystal Light to a date, and if saying “I love you” for the first time during sex means anything. With honest insights and hilarious moments J&J give their unfiltered takes!

(1:00:00) Matt Brown, Extra Points (1:30:00) Matt Tait, Wave The Wheat (1:50:00) Craig Smoak's “Off The Radar” (2:20:00) Hal Mumme, Legendary Football Coach (2:53:00) Paul Catalina's “Top 5” Learn more about your ad choices. Visit megaphone.fm/adchoices

In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes "Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma” by Dr. Miles C. Andrews, et al. published on June 07, 2024. Transcript The guest on this podcast episode has no disclosures to declare. Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights. I'm your host, Jiasen, and today we'll be discussing the JCO Precision Oncology article, "Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma," by Dr. Miles C. Andrews and colleagues. This study was supported by Foundation Medicine, a for-profit company that conducts FDA-regulated molecular diagnostics, including assays used to measure tumor mutational burdens, or TMB, as described in this article. Immune checkpoint inhibitor (ICI) therapy has become a cornerstone in the treatment of metastatic melanoma. They work by activating the patient's own immune system, representing a fundamentally different approach from traditional chemotherapy. Several biomarkers have emerged as promising tools to predict ICI therapy response, and TMB is one of the most extensively studied. TMB is defined as the number of somatic mutations per megabase of an interrogated genome sequence. In the KEYNOTE-158 study, patients with high TMB showed better response rates and longer progression-free survival compared to those with low TMB, which led to the FDA tumor-agnostic approval of TMB as a biomarker to guide ICI therapy. In this manuscript, Dr. Andrews and colleagues set out to answer an important question: does TMB predict outcomes of ICI therapy in real-world patients with advanced melanoma? To explore this, they analyzed de-identified data from the nationwide Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB). To be included, patients needed to have had at least two visits to a Flatiron Health clinic and a Foundation Medicine Comprehensive Genomic Profiling report. Eligible patients had received first-line treatment with either monotherapy (nivolumab or pembrolizumab) or dual therapy with the combination of ipilimumab and nivolumab for metastatic melanoma. They also needed a tissue-based TMB score from either the FoundationOne or FoundationOne CDx genomic test. For this study, TMB less than 10 mutations per megabase was considered low TMB; TMB equal to or more than 10 mutations per megabase was considered high TMB; and TMB equal to or more than 20 mutations per megabase was considered very high TMB. Of the 497 patients in the final cohort, 29% had low TMB, while 71% had high TMB, and 50% had very high TMB. The authors observed that patients with very high TMB were more often male, had BRAF wild-type tumors, and were more likely to receive anti-PD-1 monotherapy. This group also had tumors more commonly sampled from brain and lung metastases. Patients with high TMB but not very high TMB were more likely to carry the BRAF V600K mutation and were least likely to have lung metastases. Meanwhile, those with low TMB tended to be younger and had disease limited to non-visceral sites. As expected, the presence of ultraviolet mutation signatures, a known driver of melanoma, was strongly associated with TMB. UV signatures were found in just 18% of the low TMB group, but in 89% of the high TMB and 93% of the very high TMB group. High TMB was found to be prognostic of improved real-world progression-free survival (PFS) and overall survival (OS) in patients receiving both monotherapy and dual immune checkpoint inhibitors, even after adjusting for other established prognostic factors. Interestingly, in the low TMB group, overall survival was likely confounded by the availability of effective second-line targeted therapy, particularly for BRAF-mutant patients. These patients had better outcomes compared to their BRAF wild-type counterparts, likely reflecting a greater reliance on salvage therapy in low TMB patients who derived less benefit from first-line immunotherapy. The authors then further examined the ICI outcomes using stepwise TMB thresholds, with TMB less than 10 as low, 10 to 19 as high, and equal to or more than 20 as very high. For those receiving ICI monotherapy, both PFS and OS were highest in the very high TMB group, followed by the high TMB group, and lowest in the low TMB group. However, in patients treated with dual ICI therapy, the results diverged. While low TMB patients still had the poorest outcomes, those with high TMB (mutations 10 to 19 per megabase) had better PFS and overall survival than those with very high TMB (mutations equal to or more than 20 per megabase). The authors then conducted exploratory multivariable modeling, showing that among very high TMB patients with BRAF mutations, dual ICI therapy was associated with a significantly higher hazard ratio compared to monotherapy. They concluded that dual ICI may not benefit, and could even harm, patients with very high TMB, whereas those with TMB between 10 and 20 mutations per megabase may get more from the intensified regimen. Importantly, as the authors stated in the manuscript, we need to note that in this cohort, very high TMB patients were more likely to have brain metastases at treatment initiation, be male, and lack BRAF V600E/K mutations—all factors associated with poorer prognosis. This might partially explain inferior outcomes to dual ICI in very high TMB patients, as patients were not randomly assigned to therapy in this retrospective, real-world study. As such, these findings should be interpreted with caution and validated in future studies. In summary, this study showed that in a real-world setting, high tumor mutational burden predicts better outcomes with immune checkpoint inhibitor therapy in patients with advanced melanoma. Interestingly, the authors found that dual ICI therapy may offer no added benefit for patients with very high TMB compared to ICI monotherapy. However, this was a retrospective, non-randomized study, and the cohorts were imbalanced for some known risk factors, which could confound outcomes. As a result, these findings should be interpreted with caution and will need to be validated in future prospective studies. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this EPISODE I'm sharing on: How to increase the quality of men you attract Changes to make it simple for you to attract your husband Learning to leverage your routine to meet men you find attractive that align with your values To work with me 1-1 to go from single to married in a year Click the link below

Lancet 1999;353:2001-07Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of life with diuretics and inotropic agents like digoxin; however, new paradigms were arising that focused on addressing neurohormonal mechanisms of chronic disease that were over-activated in the failing heart. The first major success came with inhibition of the renin angiotensin aldosterone system with angiotensin converting enzyme inhibitors whose effect on mortality for patients with mild and severe forms of chronic heart failure were demonstrated in the V-HEFT II, CONSENSUS, and SOLVD trials. Additional benefits were demonstrated with the mineralocorticoid receptor antagonist spironolactone in the RALES trial. These drug classes primarily work by reducing afterload and volume retention. Appreciating why they work for improving cardiac performance and managing symptoms in heart failure patients is straightforward when we consider the major factors that effect cardiac stroke volume - preload, afterload and contractility; however, it is also noteworthy the effects these agents have on sudden death. How beta-blockade benefits the failing heart is less obvious (outside prevention of sudden death). Mechanistic studies in patients with chronic heart failure have consistently shown that when beta blockers are used for more than 1 month, left ventricular function improves. Beta blocker therapy appears to restore the density of beta-adrenergic receptors after they have been downregulated by the chronic overactivity of the sympathetic nervous system. The first major placebo-controlled RCT to demonstrate a mortality benefit used the non-selective beta blocker carvedilol. The trial was small and not originally designed to test mortality and was stopped early without clearly predefined stopping rules. Furthermore, 8% of total patients selected for participation in the trial were excluded prior to randomization after a 2 week, open-label run-in phase with the study drug, which saw 2% of all patients experience worsening heart failure or death representing 24 patients (the difference in total deaths between groups was 9 when the trial was stopped). The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) was the first large scale trial designed to test the hypothesis that beta-blockade with metoprolol controlled/extended release (CR/XL) added to optimum medical therapy reduces mortality in patients with chronic systolic heart failure.Patients: Patients were recruited from 313 sites in 13 European countries and the United States. Eligible patients were men and women between the age of 40 to 80 years with symptomatic heart failure (NYHA class II-IV) for >/= 3 months before randomization. They had to be on a diuretic and ACE inhibitor for at least 2 weeks. Other drugs, including digoxin, could also be used. Patients also had to have an EF of /=68 beats per minute.Patients were excluded if: they had an MI or unstable angina within 28 days; had an indication or contraindication for treatment with beta-blocker; beta blockade within 6 weeks; heart failure due to systemic disease (i.e., amyloidosis) or alcohol abuse; scheduled or performed cardiac transplant; an ICD; procedures such as CABG or PCI planned or performed in the past 4 months; 2nd or 3rd degree AV block unless a pacemaker was present; unstable or decompensated heart failure defined by pulmonary edema or hypoperfusion or supine systolic BP 25% deviation of the number of observed versus expected consumed placebo tablets during the run-in period.Baseline characteristics: The mean age of patients was 64 years and approximately 78% were male. Slightly more than 30% of patients were above the age of 70. The average EF was 28%. The average SBP was 130 mmHg and heart rate was 82 bpm. Most patients had mild to moderate heart failure, with 41% in NYHA Class II, 56% in Class III, and only 3% in Class IV. Ischemic cardiomyopathy accounted for 65% of cases and nonischemic causes accounted for 35%. Most patients were on an ACE inhibitor or ARB (95%) and diuretic (90%). Digoxin was used in 63%. Trial procedures: Prior to randomization, the study was preceded by a single-blind, 2-week placebo run-in period. Patients meeting eligibility were then randomized to placebo or metoprolol CR/XL. The starting dose of placebo or metoprolol CR/XL was 12.5 mg daily for patients in NYHA class III or IV and 25 mg daily for patients in NYHA class II. The dose was doubled every 2 weeks until the target dose of 200 mg daily was reached. Patients were followed every 3 months.Endpoints: The primary outcome was all-cause mortality. It was estimated that 3,200 patients would need to be followed for 2.4 years to detect a 30% relative reduction in mortality based on annual mortality rate of 9.4% in the placebo group. This would achieve at least 80% power with a 2-sided alpha of 0.04. Patients were recruited faster then planned and so the final sample size of 3,991 patients increased the power of the study.The study was monitored by an independent safety committee and predefined stopping rules for efficacy were based on all-cause mortality, done when 25%, 50%, and 75% of expected deaths had occurred. Results: The trial was stopped early after the 2nd preplanned interim analysis when 50% of expected deaths had occurred. The mean duration of follow-up at the time of stopping was 1 year. The mean daily dose of metoprolol CR/XL was 159 mg once daily, with 87% receiving 100 mg or more and 64% receiving the target dose of 200 mg daily. In the placebo group, the corresponding values were 179 mg daily, 91% and 82%. The study drug was discontinued permanently in 14% of patients in the metoprolol group and 15% in the placebo group. Six months after randomization, heart rate decreased by 14 bpm in the metoprolol group compared to only 3 bpm in the placebo group. Systolic blood pressure decreased less in the metoprolol group (-2.1 vs 3.5 mmHg).Compared to placebo, metoprolol significantly reduced all-cause mortality (7.3% vs 10.8%; RR 0.66; 95% CI 0.53—0.81). Cardiovascular mortality accounted for 91% of all deaths; with sudden death accounting for 58% and death from worsening heart failure accounting for 24% of all deaths. All 3 of these causes of death were significantly reduced by metoprolol. The relative and absolute effects on death were greatest for patients with NYHA class III heart failure.Conclusions: In this trial of stable patients with mild to moderate chronic systolic heart failure, who were optimized on an ACEi or ARB and diuretic, metoprolol CR/XL significantly reduced all-cause mortality. Approximately 30 patients would need to be treated with metoprolol compared to placebo for 1 year to prevent 1 death. This trial represents a significant win for beta blockade in patients with chronic systolic heart failure. While the NNT in this trial is slightly higher than in SOLVD, it is important to appreciate that follow-up time in SOLVD was more than 3x longer. Limitations to external validity in this trial include the run-in period and stringent inclusion and exclusion criteria. Our enthusiasm is also tempered by early stopping, which has been found to be associated with false positive or exaggerated results but this concern is mitigated to some extent in this trial because the rules for early stopping were clearly defined in the protocol.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

NFL players will be eligible to play in the flag football event at the Olympics

Last Tuesday, MLB Commissioner Rob Manfred dropped a bomb on the baseball community with his announcement that the lifetime bans of 17 individuals were lifted, effective immediately. With the ban lifted, all 17 are now eligible for the Baseball Hall of Fame, but let's be real; Pete Rose and 16 others are now eligible for Cooperstown. Jim covers what happened and walks through the list of all of the individuals impacted. Then, he takes a quick look into the Hall of Fame cases of Shoeless Joe Jackson, Eddie Cicotte, Benny Kauff, and Rose (17:35). Finally, he reviews what the 2028 Classic Baseball Era ballot could look like, which is the first ballot any of these players could potentially land on (36:47).

Learn more about your ad choices. Visit podcastchoices.com/adchoices

After 35 years behind bars for murdering their parents, Erik and Lyle Menendez will now have a chance at parole. Investigative journalist Robert Rand has covered this story since the 1989 murders of Jose and Kitty Menendez, even uncovering new evidence along the way.

See omnystudio.com/listener for privacy information.

Case gives his take on Pete Rose and Shoeless Joe Jackson becoming Hall of Fame eligible. Plus, Sean goes deep inside the mental makeup you need at the plate that he thinks has helped the likes of Trent Grishom of the Yanks to turn into a weapon at the dish. Full Youtube Broadcast Here: https://youtu.be/EMlbfmIt2ZM BetOnline is The World's Most Trusted Betting Platform and your #1 source for all your sports betting action! Baseball season is in full swing, and we're into the home stretch for NBA and NHL Playoffs has more ways to stay in on the action with the latest odds, news and scores, even LIVE in-game betting while the games are being played. With the largest selection of odds on everything from the MLB, NHL and UFC, BetOnline remains the #1 online source for all your sports wagering info. In between games head over to the BetOnline Casino with all the top Vegas style Games, including Poker and Live Casino! BetOnline - The Game Starts Here!

Big O talks Pete Rose 051425

A daily non-partisan, conversational breakdown of today's top news and breaking news stories Headlines: – Welcome To Mo News  (02:00) – ​​Trump In The Gulf: Says U.S. Will Remove All Sanctions On Syria (06:20) – Biden Aides Discussed Wheelchair Use If He Were Re-Elected, New Book Says (19:30) – United Air Warns Flyers of Reduced Newark Service Through Summer (27:40) – Annual Inflation Rate Hit 2.3% in April, Less Than Expected And Lowest Since 2021 (30:30) – Menendez Brothers Now Eligible For Parole (32:50) – AMC to Slash Movie Ticket Prices by 50% on Wednesdays (36:30) – Mosheh at The Sweet & Snacks Expo In Indianapolis (38:20) – On This Day In History (44:10) Thanks To Our Sponsors: – LMNT - Free Sample Pack with any LMNT drink mix purchase – Shopify – $1 per-month trial Code: monews – Sonic Power - 20% off | Promo Code: MONEWS – Surfshark - 4 additional months of Surfshark VPN | Code: MONEWS – Industrious - Coworking office. 30% off day pass – Athletic Greens – AG1 Powder + 1 year of free Vitamin D & 5 free travel packs

See omnystudio.com/listener for privacy information.

News Whip: Air BNB offering new features. San Clemente looking for “just right” sand. IN-N-OUT to eliminate bad dyes in their food. // Disneyland makes some changes to “It's a Small World”. Breaking news: Menendez Brothers resentenced 50 years to life, eligible for parole. #Menene // BREAKING: Menendez brothers resentencing; 50 years to life, eligible for parole // Adam Carolla's connection to Menendez brother's lawyer Mark Geragos. Carolla was the impetus for Geragos taking the Menendez case. #MarkGeragos #MenendezFree The Stand-Up Comedy Club of Bellflower 2nd show tickets available  Saturday, May 24th –10pm show. #AdamCarolla #standup #Comedy   

See omnystudio.com/listener for privacy information.

Papa & Silver Hour 1: Warriors Season on the Brink, Pete Rose Hall of Fame Eligible, & John SheaSee omnystudio.com/listener for privacy information.

John Shea joins Silver & JD to react to Pete Rose becoming Hall of Fame eligible and what it means for other great like Barry Bonds who are left out of CooperstownSee omnystudio.com/listener for privacy information.

In the second hour, Mike Mulligan and David Haugh debated if a pair of previously banned players in the late Pete Rose and "Shoeless" Joe Jackson deserve to be inducted into the Hall of Fame after baseball reinstated them Tuesday. After that, Score baseball insider Bruce Levine joined the show to discuss the Cubs' walk-off 5-4 win against the Marlins on Tuesday at Wrigley Field.

Mike Mulligan and David Haugh reacted to the late Pete Rose being reinstated by MLB, making him eligible for the Hall of Fame.

Nearly 36 years after Erik and Lyle Menendez took their parents' lives with shotguns in a crime that captivated the nation, the brothers appeared via video before a Los Angeles judge who would determine their potential release from prison.See omnystudio.com/listener for privacy information.

After MLB commissioner Rob Manfred lifted Pete Rose's lifetime ban, do you think he will be elected to the Hall Of Fame?

Trey Hendrickson, the Cincinnati Bengals' All-Pro defensive end, is embroiled in a heated contract dispute as he enters the final year of his deal, set to earn $15.8 million in 2025. After leading the NFL with 17.5 sacks in 2024, Hendrickson is pushing for a lucrative extension, frustrated by the Bengals' lack of communication since the NFL Draft. His camp reports no progress, with prior offers falling short of promises made last offseason. The Bengals, who recently signed Ja'Marr Chase and Tee Higgins to massive deals totaling $276 million, seem hesitant to meet Hendrickson's demands, possibly due to his age (31) and the team's methodical approach to contracts. Despite permission to seek a trade, no movement has occurred, raising speculation about a potential holdout. NFL insiders remain optimistic, with some believing Cincinnati will eventually pay Hendrickson, citing his critical role in their defense, which struggled last season. However, the drafting of edge rusher Shemar Stewart hints at a possible succession plan. As training camp looms, this saga could define the Bengals' 2025 season. Will they secure their star pass rusher or risk losing him? On May 13, 2025, the Cincinnati Reds fell 5-1 to the Chicago White Sox at Great American Ball Park. Andrew Abbott delivered a strong start, pitching six innings and allowing just one run on five hits. The Reds' offense, however, struggled, mustering only six hits against White Sox pitching. Trailing 1-0, Elly De La Cruz tied the game with a solo home run in the ninth. The game went to extra innings, where Miguel Vargas' three-run homer in the 10th sealed the White Sox's victory. Despite the loss, De La Cruz's late-game heroics provided a highlight for Reds fans. On May 13, 2025, MLB Commissioner Rob Manfred announced the posthumous reinstatement of Pete Rose, baseball's all-time hits leader, removing him from the permanently ineligible list 36 years after his 1989 ban for betting on games. The decision, which also reinstated 16 other deceased players like “Shoeless” Joe Jackson, means Rose is now eligible for the Baseball Hall of Fame, with potential consideration by the Classic Baseball Era Committee in December 2027. Manfred ruled that lifetime bans end upon a player's death, citing no further threat to the game's integrity. The move followed a petition from Rose's family in January 2025, after his death in September 2024 at age 83, and discussions with President Donald Trump, a vocal Rose supporter. Cincinnati Reds owner Bob Castellini celebrated the decision, calling Rose one of baseball's greatest. However, reactions were mixed: some fans and figures like Mike Schmidt praised the move, while others, including Bart Giamatti's son, argued it undermines baseball's integrity. Rose's reinstatement reopens debates about his legacy, gambling in sports, and Hall of Fame criteria, with his 4,256 hits and three World Series titles now eligible for Cooperstown's judgment.

Pete Rose now eligible for the MLB H.O.F full 583 Wed, 14 May 2025 15:51:04 +0000 DrA8fCgSmHg7pWd3VpI4GkCkjJ9M6iIs mlb,reds,society & culture Cody & Gold mlb,reds,society & culture Pete Rose now eligible for the MLB H.O.F Hosts Cody Tapp & Alex Gold team up for 610 Sports Radio's newest mid-day show "Cody & Gold."  Two born & raised Kansas Citians, Cody & Gold have been through all the highs and lows as a KC sports fan and they know the passion Kansas City has for their sports teams."Cody & Gold" will be a show focused on smart, sports conversation with the best voices from KC and around the country. It will also feature our listeners with your calls, texts & tweets as we want you to be a part of the show, not just a listener.  Cody & Gold, weekdays 10a-2p on 610 Sports Radio.  2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-link=htt

After previously being on the ineligible list, Pete Rose and Shoeless Joe Jackson are now eligible to be inducted into Baseball’s Hall of Fame. The two immensely talented players were both tainted by scandal. Rose admitted to betting on games while Jackson and seven other teammates were banned for allegedly fixing the World Series in 1919. Geoff Bennett discussed more with Howard Bryant of ESPN. PBS News is supported by - https://www.pbs.org/newshour/about/funders

BREAKING Pete Rose and Shoeless Joe Eligible for HOF, Tatum's Injury, and Visiting Australia - T H2

Hour 2 – The Drive reacted to the breaking news that the commissioner of baseball has made Peter Rose and Shoeless Joe Jackson Hall of Fame eligible.

John and Sam react to the Dallas Mavericks winning the lottery and all the permutations the lottery can have on the trade market. (0:00) Intro (1:30) The Nico Harrison Bail Out (4:55) San Antonio Spurs #2 (6:14) Does This Open Up Stephon Castle to Trade? (12:49) 76ers Move Up to #3 (20:00) Should Play-In Teams be Eligible for Top Picks? (24:00) Hornets, Jazz & Wizards (27:15) Brooklyn Nets At #8 (28:40) Houston Rockets At #10

(0:00) Mazz opens The Baseball Hour discussing the Red Sox 14-2 loss to the Detroit Tigers on Monday night. (13:55) Dan Shaughnessy joins Mazz on The Baseball Hour to discuss Pete Rose and the Hall of Fame. (28:39) Trivia Tuesday! Plus, final thoughts from the callers!